View Post

Male breast cancer: What men should know

In In The News by Barbara Jacoby

By: Lucy Richardson From: mdanderson.org As shared by: Frederick Strebel Breast cancer is typically thought of as a woman’s disease. But men develop the disease, too. And, due to a lack of awareness about male breast cancer, it’s often found at later stages, when the disease is more difficult to treat. We recently discussed male breast cancer with Sharon Giordano, …

View Post

Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations

In Clinical Trials by Barbara Jacoby

From: mdanderson.org FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of …

View Post

Q&A: Phase I clinical trials

In Clinical Trials by Barbara Jacoby

By: Devon Carter From: mdanderson.org Phase I clinical trials are the foundation for how we develop new cancer drugs. Typically, they involve only several dozen patients and study a new medicine’s effect on a variety of cancer types. David S. Hong, M.D., sat down with us to explain more about Phase I clinical trials and answer some of patients’ most …

View Post

Clinical Trials at MD Anderson

In Clinical Trials by Barbara Jacoby

From: mdanderson.org As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. Look through our database to find studies for which you may be eligible. What are clinical trials? Clinical trials are research studies in which patients may volunteer to take part. MD Anderson …

View Post

Pancreatic cancer patient in partial remission after experimental drug treatment

In Clinical Trials by Barbara Jacoby

By: Ronda Wendler From: mdanderson.org Allison Lippman was 30 years old when she was diagnosed with stage 4 pancreatic cancer. A new drug that targets her cancer’s genetic mutation has shrunk her tumors in half. Just before she was diagnosed with pancreatic cancer, Allison Lippman was on top of the world. She’d just celebrated her 30th birthday, been promoted at …

View Post

His single-cell solution is revolutionizing cancer research

In In The News by Barbara Jacoby

By: Clayton Boldt, Ph.D. From: mdanderson.org Nicholas Navin wanted to better understand how tumors grow and evolve, so he found a way to analyze the DNA of individual cells Frustration often leads to innovation. Thomas Edison himself called discontent the “first necessity of progress.” For Nicholas Navin, Ph.D., it drove him to pioneer a technique that has revolutionized the way researchers are able …

View Post

Straight to the lungs: Inhaled chemo lessens collateral damage

In Clinical Trials by Barbara Jacoby

By: Katrina Burton From: mdanderson.org MD Anderson researchers are examining the use of inhaled chemotherapy to treat cancer that has spread to the lungs from other sites in the body. They hope to find that the inhaler delivers the chemotherapy drug directly to the lungs where it treats lung tumors while sparing healthy organs. A new way of treating cancer …

View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies

In Clinical Trials by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone …